In detail, there were several pathways involving ERBB2, e.g., signaling by ERBB2 in cancer (p = 3.35E−5), downregulation of ERBB2 signaling (p = 3.35E−5), ERBB2 regulates cell motility (p = 5.03E−6), signaling by ERBB2 KD mutants (p = 3.09E−5), signaling by ERBB2 TMD/JMD mutants (p = 2E−5), ERBB2 activates PTK6 signaling (p = 4.28E−6), GRB2 events in ERBB2 signaling (p = 6.77E−6), SHC1 events in ERBB2 signaling (p = 3.35E−5). The gene discussed is PTK6; the disease is cancer.